Esperion Therapeutics Inc

1. 1

   Election of Class I Directors

   ManagementBoard: FOR

   Elect two Class I director nominees, J. Martin Carroll and Sheldon L. Koenig, each for a three-year term ending at the 2029 Annual Meeting.

2. 2

   Non-Binding Advisory Vote on Named Executive Officer Compensation

   ManagementBoard: FOR

   Non-binding advisory (say-on-pay) vote to approve the compensation of the company’s named executive officers as disclosed in the proxy statement.

   More detail

   This management proposal requests a non-binding advisory vote (a 'say-on-pay') approving the overall compensation of the company’s named executive officers as disclosed in the proxy statement. Management and the compensation committee present this vote to provide stockholders a periodic opportunity to express their view on pay practices and alignment between executive pay and company performance. The company describes its program as designed to attract and retain key executives, reward both short-term and long-term performance, and align executive financial interests with stockholder interests through a mix of cash incentive awards and equity grants that vest over multiple years. The advisory nature means the Board is not required to change compensation based on the result, but the Board and compensation committee state they will carefully consider stockholder feedback when making future decisions. Contextually, the company emphasizes achievement of corporate goals (including U.S. net sales and pipeline progress) and used a corporate performance-based cash incentive in 2025; the Board also notes engagement with investors and adjustments tied to peer benchmarking. Potential investor concerns include the prevalence of time-based versus performance-based equity, overall quantum of awards relative to company performance and dilution from equity programs; management has signaled responsiveness to such feedback. The Board recommends a vote FOR, citing the program’s design to balance measured compensation with incentives to enhance long-term stockholder value and retain talent in a competitive biopharma market. In evaluating the merits, a sophisticated analyst should weigh the company’s recent operational achievements, the link between pay and disclosed performance metrics, vesting schedules, and expected future dilution from equity grants. Given the advisory nature, the outcome primarily serves as governance feedback rather than a direct contractual change, but a negative result would likely prompt further shareholder engagement and potential plan adjustments by the compensation committee.

3. 3

   Ratification of the Appointment of Ernst & Young LLP as Independent Registered Public Accounting Firm

   ManagementBoard: FOR

   Ratify the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

4. 4

   Approval of an Amendment to the Esperion Therapeutics, Inc. 2022 Stock Option and Incentive Plan, as amended

   ManagementBoard: FOR

   Approve a fourth amendment to the 2022 Plan to increase the aggregate number of shares authorized for issuance under the plan by 7,000,000 shares (increasing the total to 30,150,000 shares).

   More detail

   Management is asking stockholders to approve a one-time 7,000,000-share increase to the company’s 2022 Stock Option and Incentive Plan to replenish the share reserve used for equity-based compensation. Management explains that share usage has accelerated due to hiring, annual grant practices, and stock-price volatility that raises the number of shares required to deliver competitive award values, and that without additional shares the company may be forced to increase cash compensation or otherwise change its incentives. The proposal emphasizes that the 2022 Plan has no automatic “evergreen” refill, so stockholder approval is required to add shares and the Board expects the requested increase to fund awards for roughly the next 12 months. The Board frames the amendment as preserving the ability to attract, retain and motivate employees and directors while arguing that the benefits to stockholders from equity-based incentives outweigh potential dilution; it also notes that the plan prohibits repricing without stockholder approval and contains annual limits and minimum vesting protections. Key governance considerations for analysts include the magnitude of the requested increase relative to outstanding shares and recent dilution trends, the company’s historic burn rate and anticipated grant needs, the absence of an evergreen feature (which gives stockholders periodic oversight), and whether awards are predominantly time‑based or performance‑based. The Board’s recommendation to vote FOR is premised on maintaining a competitive compensation program and avoiding increased cash expense; opponents might focus on dilution, frequency of renewals, and the proportion of equity granted to insiders. A sophisticated evaluation should weigh the company’s stated hiring and retention needs, recent operational performance and cash position, the expected share usage over the next year, and practices (e.g., minimum vesting, repricing restrictions) that mitigate governance risks.

Upcoming shareholder meetings at Esperion Therapeutics Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.

When is the Esperion Therapeutics Inc 2026 annual meeting?

Esperion Therapeutics Inc (ESPR) holds its 2026 annual shareholder meeting on Thursday, May 28, 2026.

What is the record date for the Esperion Therapeutics Inc 2026 meeting?

The record date for the Esperion Therapeutics Inc 2026 meeting is Tuesday, March 31, 2026. Shareholders of record on or before that date are eligible to vote.

Who are the director nominees for Esperion Therapeutics Inc's 2026 meeting?

The board is presenting 2 director nominees at the Esperion Therapeutics Inc 2026 meeting, listed with their independence status and background.

What proposals will shareholders vote on at the Esperion Therapeutics Inc 2026 meeting?

Shareholders will vote on 4 proposals at the Esperion Therapeutics Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.